04/08/14 - 11:23 AM EDT
The latest salvo was lobbed Tuesday by pharmacy benefits manager Express Scripts against Gilead Sciences and its $1,000-per-day hepatitis C pill Sovaldi. Express Scripts says the U.S. healthcare system can't afford Sovaldi so it wants to form a coalition of private employers, insurance companies and the government focused on fair drug pricing. But first, Express wants Gilead to cut the price of Sovaldi or be frozen out when competing hepatitis C therapies are approved later this year and next, according to a Bloomberg report.READ FULL POST
04/08/14 - 09:11 AM EDT
If approved next year, Alkermes' aripiprazole lauroxil will compete against several other long-acting antipsychotics, including a similar once-monthly injectable aripiprazole approved last year and sold by Otuska and Lundbeck. But the schizophrenia treatment market (oral and injectable drugs) is big and growing -- more than $11 billion in the U.S. last year and $20 billion-plus worldwide. Oral versions of aripiprazole, sold under the brand name Abilify, generated $6.5 billion in sales last year.READ FULL POST
04/03/14 - 09:00 AM EDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.READ FULL POST
04/03/14 - 08:30 AM EDT
Northwest Bio is now acknowledging that no agreement with the FDA was ever reached on the progression-free survival (PFS) primary endpoint for the DCVax phase III brain cancer study.READ FULL POST
03/31/14 - 06:54 AM EDT
The experimental drug PBT2 failed to reduce beta amyloid plaque in the brain and couldn't improve cognition or function in Alzheimer's patients.READ FULL POST
03/29/14 - 11:33 AM EDT
Northwest Biotherapeutics takes umbrage at anyone who describes the German Hospital Exemption decision for its brain cancer vaccine DCVax as "compassionate use" -- except when they do it.READ FULL POST
03/28/14 - 04:16 PM EDT
Biotech stocks continue to melt down. I know, broken record, but like a car wreck, it's hard not to look.READ FULL POST
03/27/14 - 04:21 PM EDT
Northwest Biotherapeutics CEO Linda Powers took to a podium at a conference in New York this afternoon and dribbled out some new information about the company's cancer vaccine DC-Vax and the ongoing phase III study in brain cancer. Powers is a skilled dissembler, so her update, while amazingly negative for DC-Vax, was spun positive. It was an award-winning performance.READ FULL POST
03/26/14 - 05:14 PM EDT
Novartis' ceritinib is a next-generation ALK inhibitor already under FDA review as a new treatment for lung cancer.READ FULL POST
03/26/14 - 11:42 AM EDT
Exelixis shares fall after independent data monitors concluded a closely watched phase III study of cabozantinib in advanced prostate cancer should continue to the final analysis expected later this year.READ FULL POST
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.